CClinicalTrials.gg
CompletedNCT02808494Updated Apr 29, 2022

Development of a Next Generation Sequencing (NGS) -Based Assay to Detect Preeclampsia Molecular Markers

An observational study in Preeclampsia, sponsored by Illumina, Inc.. Completed at 10 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-29.

Sponsored by Illumina, Inc. · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
242
Ages
18 Years and older
Sex
Female
01

Study summary

Sample Collection Study

Read the detailed description

This is a limited prospective collection of whole blood samples from pregnant women with a diagnosis of preeclampsia with severe features and/or fetal growth restriction in addition to samples from a control group to aid in the development of a Next Generation Sequencing (NGS)-based assay to detect molecular markers associated with preterm preeclampsia.

02

Conditions studied

  • Preeclampsia

Browse trials for

Keywords

  • Preeclampsia
  • Fetal Growth Restriction
03

In context

Pre-Eclampsia

882 studies on the registry are indexed under Pre-Eclampsia; 237 are open to participants now.

This study's enrollment of 242 is above the median of 163 across 380 observational studies indexed under Pre-Eclampsia.

Browse Pre-Eclampsia studies →

Lead sponsor

Illumina, Inc. is the lead sponsor of 12 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Affected Group: Pregnant women diagnosed with preeclampsia with severe features or fetal growth restriction

Control group: Pregnant women matched for gestational age to the Affected group above

Inclusion criteria

  1. Women 18 years of age or older at enrollment
  2. Pregnant women with a viable singleton gestation
  3. Able to provide written, informed consent
  4. Able to provide 20 mL of whole blood
  5. Diagnosis of preeclampsia with severe features and/or diagnosis of fetal growth restriction.

    1. Preeclampsia with severe features is defined as:

      Proteinuria: Excretion of ≥300mg/24hr (24 hour collection) of protein or a timed excretion that is extrapolated to the 24 hour urine value or a protein/creatinine [both in mg/dL] ratio of at least 0.3 or a qualitative determination of (urine dipstick) of ≥1+ WITH Systolic BP ≥160mmHg or diastolic BP ≥110mmHg on at least 2 occasions 4 hours apart while on bedrest but before the onset of labor OR Systolic BP ≥160mmHg or diastolic BP ≥110mmHg on 1 occasion but before the onset of labor, if antihypertensive therapy is initiated due to severe hypertension OR New onset hypertension defined as: Systolic BP ≥140 mmHg or diastolic ≥90 mmHg with one or more of the following features: Thrombocytopenia (\<100,000 plts/mL); impaired liver function (AST/ALT 2X ULN); newly developed renal insufficiency (serum creatinine >1.1mg/dL or a doubling of serum creatinine in the absence of other renal disease); pulmonary edema; new onset cerebral disturbances or scotomata

    2. Fetal Growth Restriction defined as:

    Estimated fetal weight by ultrasound at ≥ 19 0/7 weeks gestational age \< 5%ile or 5-10%ile with abnormal umbilical artery Doppler examination (S/D ratio >95%ile for gestational age, absent end diastolic flow or reverse end diastolic flow)

  6. Gestational age between 20 0/7 and 33 6/7 weeks determined by ultrasound and/or LMP per ACOG guidelines1. A subject diagnosed with preeclampsia without severe features prior to 33 6/7 weeks gestation and who is managed expectantly and develops severe features after 34 weeks may be included.

Exclusion criteria

Exclusion Criteria:

  1. Known malignancy
  2. History of maternal organ or bone marrow transplant
  3. Maternal blood transfusion in the last 8 weeks
  4. Chronic hypertension diagnosed prior to current pregnancy
  5. Type I, II or gestational diabetes
  6. Fetal anomaly or known chromosome abnormality
  7. Active labor
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
242 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Affected Group

    Women with a diagnosis of preeclampsia with severe features and/or fetal growth restriction.

  • Control/Unaffected Group

    Women who do not have a diagnosis of preeclampsia with severe features and/or fetal growth restriction.

06

What researchers measure

Primary outcomes

  1. cfRNA markers associated with preeclampsia with severe features and/or fetal growth restrictions

    Time frame: 2 years

07

Study locations

10 sites
  • Christiana Hospital
    Newark, Delaware 19718, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Saint Peter's University Hospital
    New Brunswick, New Jersey 08901, United States
  • Rutgers University
    Piscataway, New Jersey 08854, United States
  • Virtua Materna-Fetal Medicine Specialists
    Sewell, New Jersey 08080, United States
  • New York-Presbyterian/Queens
    Flushing, New York 11355, United States
  • New York-Presbyterian/Columbia University Medical Center
    New York, New York 10032, United States
  • Winthrop University Hospital Clinical Trials Center
    New York, New York 11501, United States
  • Drexel Medicine
    Philadelphia, Pennsylvania 19102, United States
  • The University of Texas Medical Branch
    Galveston, Texas 77555, United States
08

References and documents

Publications

  • Munchel S, Rohrback S, Randise-Hinchliff C, Kinnings S, Deshmukh S, Alla N, Tan C, Kia A, Greene G, Leety L, Rhoa M, Yeats S, Saul M, Chou J, Bianco K, O'Shea K, Bujold E, Norwitz E, Wapner R, Saade G, Kaper F. Circulating transcripts in maternal blood reflect a molecular signature of early-onset preeclampsia. Sci Transl Med. 2020 Jul 1;12(550):eaaz0131. doi: 10.1126/scitranslmed.aaz0131. PubMed 32611681 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02808494
Lead sponsor
Illumina, Inc.
Responsible party
Sponsor
First posted
Jun 21, 2016
Start date
Mar 2016
Primary completion
Nov 20, 2017
Completion
Nov 20, 2017
Last update
Apr 29, 2022

Study contacts

Matthew Rhoa, MD
study director · Illumina, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion